These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30012774)

  • 1.
    Smith RA; Wu VH; Zavala CG; Raugi DN; Ba S; Seydi M; Gottlieb GS;
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.
    Smith RA; Raugi DN; Wu VH; Zavala CG; Song J; Diallo KM; Seydi M; Gottlieb GS;
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30803972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A literature review of the patent application publications on cabotegravir - an HIV integrase strand transfer inhibitor.
    Kovač L; Časar Z
    Expert Opin Ther Pat; 2020 Mar; 30(3):195-208. PubMed ID: 31944142
    [No Abstract]   [Full Text] [Related]  

  • 4. Formulation and pharmacology of long-acting cabotegravir.
    Trezza C; Ford SL; Spreen W; Pan R; Piscitelli S
    Curr Opin HIV AIDS; 2015 Jul; 10(4):239-45. PubMed ID: 26049948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabotegravir long-acting for HIV-1 prevention.
    Andrews CD; Heneine W
    Curr Opin HIV AIDS; 2015 Jul; 10(4):258-63. PubMed ID: 26049951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1.
    McPherson TD; Sobieszczyk ME; Markowitz M
    Expert Opin Investig Drugs; 2018 Apr; 27(4):413-420. PubMed ID: 29633869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects.
    Ford SL; Sutton K; Lou Y; Zhang Z; Tenorio A; Trezza C; Patel P; Spreen W
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabotegravir Plus Rilpivirine: First Approval.
    Markham A
    Drugs; 2020 Jun; 80(9):915-922. PubMed ID: 32495274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
    Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
    Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabotegravir (Apretude) for Pre-exposure Prophylaxis for HIV Type 1 Infection.
    El-Haddad A; Erlich D
    Am Fam Physician; 2023 May; 107(5):545-546. PubMed ID: 37192084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Acting Cabotegravir for HIV/AIDS Prophylaxis.
    Engelman KD; Engelman AN
    Biochemistry; 2021 Jun; 60(22):1731-1740. PubMed ID: 34029457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.
    Smith RA; Raugi DN; Wu VH; Leong SS; Parker KM; Oakes MK; Sow PS; Ba S; Seydi M; Gottlieb GS;
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7437-46. PubMed ID: 26392486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxis.
    Shaik JS; Weld ED; Edick S; Fuchs E; Riddler S; Marzinke MA; D'Amico R; Bakshi K; Lou Y; Hendrix C; Han K; Ford SL; Margolis D; Spreen W; Patel P
    Br J Clin Pharmacol; 2022 Feb; 88(4):1667-1678. PubMed ID: 34240467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabotegravir: its potential for antiretroviral therapy and preexposure prophylaxis.
    Stellbrink HJ; Hoffmann C
    Curr Opin HIV AIDS; 2018 Jul; 13(4):334-340. PubMed ID: 29746267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.
    Zhou T; Su H; Dash P; Lin Z; Dyavar Shetty BL; Kocher T; Szlachetka A; Lamberty B; Fox HS; Poluektova L; Gorantla S; McMillan J; Gautam N; Mosley RL; Alnouti Y; Edagwa B; Gendelman HE
    Biomaterials; 2018 Jan; 151():53-65. PubMed ID: 29059541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis.
    Prather C; Jeon C
    Am J Health Syst Pharm; 2022 Oct; 79(21):1898-1905. PubMed ID: 35894204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.
    Landovitz RJ; Zangeneh SZ; Chau G; Grinsztejn B; Eron JJ; Dawood H; Magnus M; Liu AY; Panchia R; Hosseinipour MC; Kofron R; Margolis DA; Rinehart A; Adeyeye A; Burns D; McCauley M; Cohen MS; Currier JS
    Clin Infect Dis; 2020 Jan; 70(2):319-322. PubMed ID: 31125395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
    Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
    Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
    Murray MI; Markowitz M; Frank I; Grant RM; Mayer KH; Hudson KJ; Stancil BS; Ford SL; Patel P; Rinehart AR; Spreen WR; Margolis DA
    HIV Clin Trials; 2018 Aug; 19(4):129-138. PubMed ID: 30445896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2.
    Smith RA; Raugi DN; Pan C; Sow PS; Seydi M; Mullins JI; Gottlieb GS;
    Retrovirology; 2015 Feb; 12():10. PubMed ID: 25808007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.